Combination (Fixed-Dose Combination) Drugs: Ban on 16 Irrational FDCs (2026) – Public Health, AMR and Drug Regulation

Recent Developments:

• The Ministry of Health and Family Welfare has prohibited the manufacture, sale and distribution of 16 Fixed-Dose Combination (FDC) drugs under Section 26A of the Drugs and Cosmetics Act, 1940 with immediate effect.
• The ban follows the recommendations of an Expert Committee constituted by the Drugs Technical Advisory Board (DTAB) after a Supreme Court-directed review of FDCs available in the market.
• The prohibited FDCs were found to lack therapeutic justification, scientific evidence and favourable risk-benefit balance, while some combinations were considered capable of aggravating Antimicrobial Resistance (AMR).

Fixed-Dose Combination (FDC) Drugs:

• A Fixed-Dose Combination (FDC) is a pharmaceutical formulation containing two or more Active Pharmaceutical Ingredients (APIs) in a single dosage form such as a tablet, capsule, syrup, injection or topical cream.
• FDCs are used for treating infectious diseases, diabetes, hypertension, cardiovascular disorders, pain, respiratory diseases and dermatological conditions.
• Properly designed FDCs can improve patient compliance, simplify treatment regimens, reduce pill burden and enhance therapeutic outcomes.

Rational and Irrational FDCs:

• A Rational FDC combines medicines with complementary mechanisms of action, compatible pharmacological properties and strong clinical evidence demonstrating superior benefit over separate administration.
• A Rational FDC should also maintain appropriate dose proportions, similar pharmacokinetic profiles and an acceptable safety profile.
• An Irrational FDC combines drugs without scientific justification, established therapeutic advantage or adequate clinical trial evidence.
• Irrational combinations may expose patients to unnecessary medicines, higher toxicity, adverse drug interactions and increased treatment costs.

Regulatory Framework in India:

• The Central Drugs Standard Control Organisation (CDSCO) is India's national drug regulatory authority under the Ministry of Health and Family Welfare.
• The Drug Controller General of India (DCGI) functions under CDSCO and is responsible for approval of new drugs, certain FDCs and clinical trials.
• The Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules regulate the approval, manufacture, import, sale and quality control of drugs in India.
• Section 26A of the Drugs and Cosmetics Act, 1940 empowers the Central Government to prohibit the manufacture, sale or distribution of drugs in the interest of public health.
• New FDC approvals require scientific evaluation, safety data, efficacy evidence and regulatory clearance before marketing.

Why were 16 FDC Drugs Banned?

• The Expert Committee concluded that these combinations lacked therapeutic justification and sufficient scientific evidence.
• The risk associated with these combinations outweighed their expected clinical benefits.
• Several antibiotic combinations were considered capable of promoting irrational antibiotic use and accelerating Antimicrobial Resistance (AMR).
• Certain dermatological combinations containing aloe vera and multiple herbal ingredients lacked convincing evidence demonstrating superior efficacy over individual ingredients.

Illustrative Examples of Irrational FDCs:

• Amoxicillin + Serratiopeptidase:
• Serratiopeptidase is acid-labile and may be degraded before systemic absorption.
• Clinical evidence does not establish additional therapeutic benefit when combined with amoxicillin.
• Major treatment guidelines do not recommend this combination.
• Norfloxacin + Tinidazole:
• Norfloxacin primarily treats bacterial infections, whereas Tinidazole targets protozoal infections.
• Simultaneous bacterial and protozoal infections are uncommon, making routine combined use scientifically unjustified.
• Amoxicillin + Clavulanic Acid:
• Clavulanic acid inhibits beta-lactamase enzymes produced by resistant bacteria.
• Its indiscriminate use in infections without resistant organisms unnecessarily increases antibiotic exposure and contributes to AMR.

Antimicrobial Resistance (AMR):

• Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi or parasites evolve resistance, making antimicrobial medicines ineffective.
• Irrational antibiotic combinations increase selective pressure, enabling resistant microorganisms to survive and proliferate.
• AMR increases treatment failure, prolonged illness, healthcare expenditure, mortality and the need for expensive reserve antibiotics.
• Preserving the effectiveness of existing antibiotics is a critical component of global public health policy.

Concerns with Dermatological FDCs:

• Many dermatological FDCs combine aloe vera, Vitamin E, jojoba oil, olive oil, tea tree oil and other herbal ingredients without robust comparative evidence.
• Long market availability alone does not establish scientific validity or clinical superiority.
• Steroid-antifungal combinations may suppress local immune responses, mask fungal infections and facilitate persistent or resistant infections.

Risks Associated with Irrational FDCs:

• Patients may experience unnecessary adverse drug reactions and allergic responses because of additional ingredients.
• Fixed-dose formulations limit dose flexibility, preventing independent adjustment of individual medicines.
• Unnecessary exposure to antibiotics increases antimicrobial resistance and compromises future treatment options.
• Irrational FDCs may delay accurate diagnosis by masking disease progression while increasing treatment costs.

Measures to Promote Rational Drug Use:

• Doctors should prescribe evidence-based medicines supported by high-quality clinical studies.
• Pharmacists should remain updated regarding banned FDCs and promote rational dispensing practices.
• Patients should avoid assuming that medicines containing multiple ingredients are automatically superior.
• Health authorities should strengthen pharmacovigilance, antimicrobial stewardship programmes, prescription audits and public awareness campaigns.
• Periodic scientific review of marketed FDCs should continue to eliminate irrational formulations.

Related Institutions and Committees:

• Central Drugs Standard Control Organisation (CDSCO) regulates drug approval and quality standards.
• Drug Controller General of India (DCGI) approves new drugs and many FDCs.
• Drugs Technical Advisory Board (DTAB) is the highest statutory technical advisory body on drugs.
• Indian Council of Medical Research (ICMR) provides scientific guidance on public health issues including AMR.
• National Centre for Disease Control (NCDC) coordinates surveillance and national action against AMR.

UPSC Value Addition:

Important Provisions:

• Section 26A, Drugs and Cosmetics Act, 1940 empowers the Central Government to prohibit drugs in public interest.
• DTAB is the highest statutory technical advisory body constituted under the Drugs and Cosmetics Act, 1940.
• CDSCO functions under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.
• DCGI heads CDSCO and oversees approvals for new drugs, clinical trials and specified FDCs.

Exam-Relevant Concepts:

• Active Pharmaceutical Ingredient (API): The biologically active substance responsible for the therapeutic effect of a medicine.
• Antimicrobial Stewardship: Coordinated interventions that promote appropriate antimicrobial use to improve patient outcomes while reducing resistance.
• Pharmacovigilance: Continuous monitoring, assessment and prevention of adverse effects associated with medicines after their approval.
• Evidence-Based Medicine (EBM): Clinical decision-making based on the best available scientific evidence, physician expertise and patient needs.

Beta-Lactamase Inhibitors: Agents such as clavulanic acid that protect certain antibiotics by inhibiting bacterial enzymes responsible for antibiotic degradation